Atypical adenoma of the thyroid is a rare form of tumor, and its accurate diagnosis prior to surgical resection is difficult as the histological and pathological morphologies are very similar to those of anaplastic thyroid carcinoma (ATC), and its anaplastic transformation remains to be elucidated. We reported a case of a 75-year-old female with a thyroid isthmus nodule diagnosed repeatedly by FNAC as anaplastic carcinoma. Both the first and second FNAC specimen slides showed a large number of scattered or aggregated atypical cells consisting of large, pleomorphic nuclei with irregular membranes, chromatin clumps and prominent nucleoli. The morphology of the surgical specimen was similar to that of an anaplastic carcinoma and although it showed signs of transition from a normal follicular epithelium, there was no invasive growth or mitosis. This lesion was diagnosed as an atypical adenoma, and a papillary carcinoma was also present in the right lobe of the thyroid. Here we evaluate the molecular features of atypical adenomas in comparison with 9 ATC samples, and discuss whether or not atypical adenomas represent a form of premalignant lesion.
Ki-67 expression was found to be very low in atypical adenomas whereas all ATC samples showed high levels of Ki-67 expression. Epithelial-mesenchymal transition (EMT) marker expression suggested that atypical adenomas maintain their epithelial phenotype to a higher degree than do ATCs. Differential diagnosis between ATC and atypical adenoma is difficult by cytological and histological methods alone, and Ki-67 and EMT marker expression may support the diagnosis.
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| I N T R O D U C T I O N
Atypical adenoma of the thyroid is a rare type of benign tumor, categorized as a variant of follicular adenoma, that show spontaneous necrosis, infarction, numerous mitoses, or unusual cellularity, and which lack any evidence of capsular or vascular invasion. Its morphologic features resemble those of certain malignancies.
1,2 However, follow-up studies have
shown that these tumors behave in a benign fashion. 1, 3, 4 Most of the previous reports of atypical adenoma have been small case reports, and no molecular marker has yet been able to distinguish between atypical adenoma and anaplastic thyroid carcinoma (ATC). 5 It is, therefore, difficult to accurately diagnose atypical adenoma using fine-needle aspiration cytology (FNAC). If a definite diagnosis of atypical adenoma can be made prior to surgery, minimum surgical resection or observation should be selected. . We report a rare case of atypical adenoma which was twice diagnosed as ATC by FNAC and coexisted with a papillary carcinoma. We also discuss the potential for malignant transformation through a comparison of the expression of Ki-67, epithelial-mesenchymal transition (EMT) markers and a number of growth factors in atypical adenomas and ATC samples.
| P A T I E N T
A 75-year-old female was diagnosed with hyperthyroidism at 55 years of age and subsequently treated with thiamazole for 8 years. Her
Hiromitsu Hatakeyama and Kimiko Hoshino contributed equally to this study. Furthermore, PET-CT scans were obtained, and no distant or lymph node metastasis was detected. The maximum standardized uptake value (SUVmax) of the thyroid nodule in the isthmus was 1.6, which is lower than that for an undifferentiated cancer ( Figure 1C,D) . Although a diagnosis of a benign thyroid nodule was made on the basis of the ultrasonography and PET-scan review, total thyroidectomy with central neck dissection was performed as ATC was diagnosed on the basis of the second cytological examination and the fact that the nodule in right thyroid lobe was suspected of being a papillary carcinoma. The tumor did not invade the anterior cervical muscles, recurrent nerve, or trachea. The subsequently excised specimen was processed pathologically and studied immunohistochemically.
| R E S U L T S 3.1 | Cytological findings
The slides of the first FNAC specimen obtained in the local hospital
showed a large number of scattered or aggregated atypical cells consisting of large, pleomorphic nuclei with irregular membranes, chromatin clumps, and prominent nucleoli (Figure 2A,B) .
The second FNAC specimen, which was obtained in our institute, also showed a large number of pleomorphic atypical cells similar to the first cytology slides, as well as multinuclear cells and spindle cells, and a diagnosis of ATC was made on the basis of the second FNAC.
| Histological findings
The nodule in the isthmus showed a focal and palisaded arrangement (1) showed a transitional form from a normal follicular epithelium, (2) no invasive growth, division of the nuclei, or clumped euchromatin were observed, and (3) tumor cells with deformed nuclei are known to Low (11) appear in atypical adenoma ( Figure 2C,D) . The other nodule in the right lobe presented as a typical papillary carcinoma. Metastatic papillary carcinoma cells were detected in 2 lymph nodes in the pretracheal and paratracheal area, but no anaplastic or poorly differentiated carcinoma lymph node metastasis was observed.
| MATERIALS A ND METHODS
Aspiration was performed using a 23-gauge needle under ultrasound guidance, and the alcohol-fixed smears were Papanicolaou stained. The minutes at 37.88C, followed by reaction with a streptavidin-biotin horseradish peroxidase complex. Evaluation of the immunohistochemical staining of all molecular markers was performed as reported previously. 7 Vimentin, which was not included in the above, was evaluated for cytoplasmic staining semi-quantitatively. The scoring systems are summarized in Table 1 
| Immunohistochemical findings
To investigate the molecular biological features of atypical adenoma, we undertook immunohistochemical staining using several molecular markers associated with tumor aggressiveness and compared the results obtained for atypical adenoma and 9 anaplastic cancer samples.
FIG URE 3
Ki-67 and E-cadherin expression in the atypical adenoma and anaplastic thyroid carcinoma samples. In the atypical adenoma, less than 1% of cells were stained with Ki-67 (A), whereas Ki-67 was highly expressed in the ATC samples (B).E-cadherin was strongly expressed in the atypical adenoma (C) and weakly expressed in the ATC samples (D). [Color figure can be viewed at wileyonlinelibrary.com]
The immunohistochemical staining data for all 9 anaplastic cancer samples are summarized in Table 2 .
Ki-67 is a nuclear protein associated with cellular proliferation through ribosomal RNA transcription and is used as a marker for grading the malignancy of thyroid tumors. 8, 9 <1% of cells were stained in the atypical adenoma ( Figure 3A) , whereas 30-90% of cells in the ATC samples were stained with Ki-67 ( Figure 3B ).
Beta-catenin and E-cadherin are associated with cell-cell adhesion and their expression is usually used as an epithelial marker. 10 Both epithelial markers were highly expressed in the atypical adenoma ( Figure   3C ); however, E-cadherin expression was absent in eight of the 9 ATC samples ( Figure 3D ), and 6 of the 9 ATC samples showed only low beta-catenin expression. Vimentin is used as a mesenchymal marker.
Vimentin expression was low in the atypical adenoma, but 5 of the 9 ATC samples showed high levels of vimentin expression.
Recently, targeted molecular therapy has been used against thyroid cancer to some effect. 11, 12 The EGFR and VEGF signaling pathways are the most popular targets for this therapy; therefore, EGFR and VEGF expressions were examined. EGFR expression was high in the atypical adenoma and in 89% of ATCs, whereas VEGF expression was moderate in the atypical adenoma and varied among the ATC samples.
| DISCUSSION
Atypical adenoma is rare and shows morphologic features very similar to those of ATC, both in cytological and histological terms. In this case reported herein, our clinical cytologists diagnosed ATC without suggesting the possibility of an atypical adenoma. Several reports have argued that there is no effective method of distinguishing between these tumors based on cytological methods alone. 13, 14 Immunohistochemical analysis using Ki-67 and epithelial markers appears to provide a good option for differential diagnosis. However, the question arises as to whether accurate diagnosis prior to surgery would allow surgeons to choose a wait-and-see policy. If atypical adenoma is a premalignant lesion associated with ATC, surgical resection is recommended prior to malignant transition as the prognosis for patients with ATC is generally very poor because of its rapid growth and high frequency of distant metastasis. 15, 16 Detection of the biological mechanism underlying carcinogenesis in ATC may provide more specific treatment targets, and atypical adenoma seems to be one of the best models with which to investigate the mechanism of carcinogenesis in ATC. Several reports have discussed the notion of whether ATC is derived from atypical adenoma, PTC, follicular nodules or follicular carcinoma. 7, 17 Mutation studies have shown that BRAF mutations were detected in 29% to 69% of PTCs and in 10% to 35% of ATCs. On the other hand, TP53
mutations were found in 0% to 5% of PTCs and 67% to 88% of ATCs. [18] [19] [20] [21] These genetic findings suggest that carcinogenetic mechanism differs between ATC and PTC. Tzen et al. demonstrated TP53 mutations in atypical adenoma and suggested that ATC was derived not from PTC, but follicular carcinoma or atypical adenoma.
14 EMT enhances the aggressiveness of epithelial cancer cells and induces metastasis, local invasion and drug resistance. 22 Our study suggests that ATC loses its epithelial phenotype, whereas atypical adenoma maintains its epithelial phenotype. Several reports have shown that higher expression levels of ZEB1 and Snail1, which activate EMT, in ATCs than in other thyroid tumors. [23] [24] [25] Therefore, EMT may also be involved in malignant change in thyroid tumor
In conclusion, cytological methods alone could not distinguish between ATC and atypical adenoma; however, immunohistochemical staining with Ki-67 and EMT marker may support the histological diagnosis of atypical adenoma.
